Drug discovery solutions for obesity research
Drive your drug discovery efforts forward with our tailored solutions designed to meet the unique challenges of obesity research.
Tools to investigate hormone-based therapeutic targets for obesity treatment
Browse our curated range of precision antibodies and ELISA kits to find the right tools to support your research.
Product highlights
Anti-GLP-1R antibody [EPR21819]
- Top-cited antibody for this target
- Excellent staining in pancreas tissue
- Highlighted in a review from the Lancet group of journals3 for detecting the endogenous protein
- Highlighted by a research group at the University of Copenhagen4 showing clear membrane-localized labeling of pancreatic islets
- Suitable for WB, IHC-Fr and IHC-P; reacts with mouse and rat samples
Anti-Glucagon antibody [EP3070]
- Top-cited recombinant antibody to this target (>100 citations)
- Extensively validated in human, mouse and rat pancreatic tissues and cell lines
- Seven 5* reviews
- Suitable for IHC-P and WB; reacts with human, mouse and rat samples
Human GLP1 (7-36) ELISA Kit
- Detects active peptide (7-36)
- Measures human GLP-1 with picogram sensitivity (25 pg/mL)
- Validated in multiple biological sample types
- Single-wash 90-minute protocol
References
- Gribble, F. M. & O’Rahilly, S. Obesity therapeutics: The end of the beginning. Cell Metabolism 33, 705–706 (2021).
- Jastreboff, A. M. & Kushner, R. F. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annual Review of Medicine 74, 125–139 (2023).
- DJ;, A. J. J. Reagents and models for detecting endogenous GLP1R and GIPR. EBioMedicine (2021).
- Bjørnholm, K. D. et al. Decreased expression of the GLP-1 receptor after segmental artery injury in mice. Journal of Endocrinology 248, 289–301 (2021).
Recombinant antibodies to adipogenesis and lipid metabolism markers
Streamline your study of critical obesity pathways and biomarkers with our precision, extensively validated recombinant antibodies.
Product highlights
Anti-FABP4 antibody [EPR3579]
- Top-cited antibody for this target with >100 citations
- Suitable for mIHC, WB, ICC/IF and IHC-P; reacts with human, mouse and rat samples
- Optimized for the Leica® BOND™ system
- Fluorescence multiplex immunohistochemistry data available, featuring specific staining in adipocytes
Anti-Fatty Acid Synthase antibody [EPR7466]
- Over 80 citations
- Validated for WB, IHC-P, IP, ICC/IF and flow cytometry (intra)
- Reacts with human, mouse and rat samples
- Knock-out validated
Immunoassays to adipogenesis and lipid metabolism
Our SimpleStep ELISA® kits are potent tools for screening multiple proteins of interest, generating data in just 90 minutes without compromising on performance. Powered by our recombinant antibodies, our kits are highly sensitive and specific, and provide reproducible results between assays and between labs.
Product highlights
Human Leptin ELISA Kit
- Single-wash 90-minute protocol
- Measures human leptin with high sensitivity (4.65 pg/mL)
- Validated in plasma, cell culture supernatants, and serum
Mouse Adiponectin ELISA Kit
- Over 80 citations
- Validated for WB, IHC-P, IP, ICC/IF and flow cytometry (intra)
- Reacts with human, mouse and rat samples
- Knock-out validated
Bioassays for obesity research
Explore our curated range of assay kits and discover how our kits can help you quantify free fatty acids, triglycerides, cholesterol, carbohydrate metabolism, oxidative stress and more.
Product highlights
Free Fatty Acid Assay Kit – Quantification
- No-wash, addition-only assay with two 30-minute incubations
- Can be used with bodily fluids, culture supernatants and cell/tissue lysates
- Colorimetric, fluorometric and luminescent readouts
Triglyceride Assay Kit – Quantification
- No-wash assay with two incubation steps (20 and 60 minutes)
- Can be used with urine, plasma, tissue extracts, serum, other biological fluids and cell lysates
- Colorimetric, fluorometric and luminescent readouts
As obesity rates have risen, our understanding has evolved to recognize the condition as a complex, multifactorial disease characterized by energy balance dysregulation. The need for effective pharmacotherapeutics has never been so urgent.
We collaborate with key opinion leaders in obesity research to develop proteomic tools that accelerate your drug discovery efforts. Our reagents can take you from start to end in the drug development process, from early-stage target identification and validation to late-stage clinical trials and biomarker development.
Our broad range of gold-standard reagents features highly specific recombinant antibodies and kits, validated across applications and species to ensure the precision and reproducibility your work requires.